ALIM Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 18:37):

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally...

Stats
Šios dienos apimtis	11 651.00
Vidutinė apimtis	71 855.00
Rinkos kapitalizacija	177.55M
EPS	$0 ( 2024-03-07 )
Kita pelno data	( $-0.0400 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.04
ATR14	$0.0310 (0.91%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Ashman Philip	Sell	12 103	Common Stock
2024-03-11	Werner Jason M.	Buy	1 800	Restricted Stock Units
2024-03-11	Wood Todd Michael	Buy	125 000	Performance-Based Restricted Stock Units
2024-03-11	Wood Todd Michael	Buy	125 000	Restricted Stock Units
2024-03-11	Eiswirth Richard S Jr	Buy	14 700	Restricted Stock Units

INSIDER POWER
27.02
Last 77 transactions
Buy: 33 555 909 \| Sell: 20 075 544

Tūris Koreliacija

Ilgas: -0.07 (neutral)

Trumpas: 0.97 (very strong)

Signal:(39.524) Expect same movement, but be aware

Alimera Sciences Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ADV	0.943
RCMT	0.942
BTWN	0.941
AMZN	0.933
USLM	0.933
KE	0.93
RXST	0.929
HUSN	0.928
MRAM	0.928
ALTO	0.928

10 Labiausiai neigiamai susiję koreliacijos
AKU	-0.948
IMBI	-0.942
AMRB	-0.936
RMBS	-0.93
STRM	-0.928
AGRI	-0.927
ENNV	-0.924
LOPE	-0.923
EYEN	-0.921
PTMN	-0.919

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Alimera Sciences Inc Koreliacija - Valiuta/Žaliavos

0.58
( weak )

0.34
( neutral )

0.39
( neutral )

0.72
( moderate )

-0.52
( weak negative )

-0.44
( neutral )

Alimera Sciences Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$80.75M
Bruto pelnas:	$61.17M (75.75 %)
EPS:	$-0.790

FY	2023
Pajamos:	$80.75M
Bruto pelnas:	$61.17M (75.75 %)
EPS:	$-0.790

FY	2022
Pajamos:	$54.13M
Bruto pelnas:	$46.15M (85.26 %)
EPS:	$-2.59

FY	2021
Pajamos:	$59.03M
Bruto pelnas:	$52.00M (88.09 %)
EPS:	$-0.854

Financial Reports:

No articles found.

Alimera Sciences Inc

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.